Yujia Wen

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Challenges and Gaps in Clinical Trial Genomic Data Management

UNC Libraries(2024)10.17615/kaqf-dw34

Top 100%

0DataRank

Top 100%0 citations

Kurt R. Mueller, Samina Asad, Daniel G. Stover, Charles M. Perou, Yujia Wen +5 more

Papers

Driven by 23 papers — median percentile 0. Top paper: “Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma”.

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine(2024)10.1056/nejmoa2401726

N/A

3.9DataRank · unranked

151 citations

Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Atul Parikh +35 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.6_suppl.tps366

N/A

0.494DataRank · unranked

26 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502

npj Breast Cancer(2024)10.1038/s41523-024-00683-x

N/A

0.419DataRank · unranked

7 citations

Roberto Salgado, Oleksander Savenkov, Karla V. Ballman, Erica L. Mayer, Mark Jesus M. Magbanua +11 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.tps760

N/A

0.396DataRank · unranked

13 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +7 more

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4607

N/A

0.385DataRank · unranked

12 citations

Karla V. Ballman, Matt D. Galsky, Michael J. Morris, Ronald C. Chen, Timothy A. Chan +9 more

PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps5100

N/A

0.345DataRank · unranked

9 citations

Karla V. Ballman, Atish D. Choudhury, Ronald C. Chen, Colleen Watt, Yujia Wen +8 more

Quantitation of Cabozantinib in Human Plasma by LC–MS/MS

Journal of Chromatographic Science(2021)10.1093/chromsci/bmab090

N/A

0.328DataRank · unranked

6 citations

Julianne L. Holleran, Robert A. Parise, Michelle A. Rudek, Jennifer A. Chan, Yujia Wen +4 more

Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy

Communications Medicine(2025)10.1038/s43856-024-00728-z

N/A

0.292DataRank · unranked

6 citations

Heinz‐Josef Lenz, Gianluigi Pillonetto, Raúl Méndez-Giráldez, Hanna K. Sanoff, Reza Hadi +17 more

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps3154

N/A

0.269DataRank · unranked

5 citations

Elad Sharon, Jennifer Le‐Rademacher, Erin Twohy, Tyler Zemla, Yujia Wen +8 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps5107

N/A

0.241DataRank · unranked

4 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma

Cancer Research Communications(2024)10.1158/2767-9764.crc-22-0516

N/A

0.216DataRank · unranked

2 citations

Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Priya Kumthekar +16 more

Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers

Cell Reports Medicine(2025)10.1016/j.xcrm.2025.102154

N/A

0.212DataRank · unranked

3 citations

Aranzazu Fernandez-Martinez, Tanmayi D. Vashist, Matthew V. Holt, LaTerrica Williams, Jonathan T. Lei +26 more

Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.1010

N/A

0.203DataRank · unranked

2 citations

Roberto Salgado, Oleksandr Savenkov, Karla V. Ballman, Mark Jesus M. Magbanua, Sherene Loi +11 more

Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.325

N/A

0.202DataRank · unranked

2 citations

Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Sawyer Jacobson +12 more

Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.343

N/A

0.184DataRank · unranked

1 citations

Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Qian Shi, Sawyer Jacobson +12 more

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4562

N/A

0.104DataRank · unranked

1 citations

Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat Al‐Ahmadie, Jonathan E. Rosenberg +12 more

MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4609

N/A

0.104DataRank · unranked

1 citations

Karla V. Ballman, Matt D. Galsky, Michael J. Morris, Srikala S. Sridhar, Ronald C. Chen +7 more

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance)

ESMO Open(2025)10.1016/j.esmoop.2025.105848

N/A

0.104DataRank · unranked

1 citations

Susan M. Geyer, Andrew B. Nixon, Federico Innocenti, Q. Shi, Steven Jacobson +15 more

Challenges and Gaps in Clinical Trial Genomic Data Management

UNC Libraries(2024)10.17615/kaqf-dw34

Top 100%

0DataRank

Top 100%0 citations

Kurt R. Mueller, Samina Asad, Daniel G. Stover, Charles M. Perou, Yujia Wen +5 more

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.tps194

N/A

0DataRank · unranked

5 citations

Glenn Heller, Charles J. Ryan, David James VanderWeele, Lionel D. Lewis, Alan Tan +10 more

MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11

UNC Libraries(2020)10.17615/bhpk-5y17

N/A

0DataRank · unranked

0 citations

Geoffrey L. Greene, Charles M. Perou, Yujia Wen, Seo Young Park, Ya-Fang Chang +14 more

Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy

UNC Libraries(2025)10.17615/rbz3-7m15

N/A

0DataRank · unranked

0 citations

Scott Kopetz, Rashid, Naim U, Mark J. Ratain, Esmat Samiei, Federico Innocenti +18 more

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4521

N/A

0DataRank · unranked

0 citations

Susan Halabi, Bin Luo, Jonathan E. Rosenberg, Woonyoung Choi, Hikmat Al‐Ahmadie +12 more

Yujia Wen

Indexed papers

Top data-sharing exemplar

Papers